- Use of nonplatinum chemotherapy or targeted therapy to prolong platinum-free interval (PFI) is associated with poorer survival in patients with epithelial ovarian cancer (EOC) recurring 6-12 months after primary chemotherapy.
Why this matters
- Findings highlight the importance of platinum chemotherapy in recurrent EOC.
- Study of 177 patients with recurrent EOC and PFI of 6-12 months after primary chemotherapy.
- PFI1: time from last chemotherapy to date of recurrence.
- PFS2: time from second-line chemotherapy to initiation of third-line chemotherapy.
- Funding: None disclosed.
- Median PFI1 was 8.2 (95% CI, 8-9) months.
- 28% of patients did not receive second-line platinum-based chemotherapy.
- Median PFI1 was significantly longer with platinum-based chemotherapy vs nonplatinum therapy in the second line (8.4 vs 7.6 months; P=.013).
- Patients received a median of 4.0 treatment lines.
- Second-line platinum chemotherapy prolonged median PFS2 vs:
- Nonplatinum therapy: 7.1 vs 3.0 months (P=.0114).
- Targeted therapy: 7.1 vs 3.0 months (P=.0431).
- Median OS was longer in patients receiving platinum vs nonplatinum therapy in the second line (43.6 vs 37.6 months; P=.0174).
- Retrospective design.